戻る
TScan Therapeutics Inc (TCRX)価格
TCRX 株価推移チャート
TCRX 収入
TScan Therapeutics Inc
$1.13
-0.87%
$-0.01
終値： Jan 16, 16:00:00 GMT-5
$1.15
1.77%
$0.02
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$1.14
始値
$1.12
当日レンジ
$1.12 - $1.19
52週レンジ
$0.882 - $2.67
取引高
643.4K
平均取引高
778.3K
1株当たり利益(TTM)
-1.12
配当利回り
--
時価総額
$65.2M
TCRXとは何ですか？
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.